Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Clinical trial NCT02709889 · TERMINATED

Trial details

NCT number: NCT02709889
Sponsor: AbbVie
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma Medullary Thyroid Cancer Glioblastoma Large-Cell Neuroendocrine Carcinoma Neuroendocrine Prostate Cancer High Grade Gastroenteropancreatic Neuroendocrine Carcinoma Other Neuroendocrine Carcinoma Other Solid Tumors

Start date: 2016-09-23
Primary completion: 2019-08-27
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.